Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.61 |
| ▸ | HEXA | P06865 | 1/20 | 0.61 |
| ▸ | HEXB | P07686 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289229 | 0.90 | ALDH1A1 (0.55) | DHFRHEXAHEXBALDH1A1HPGD | |
| SCHEMBL7162150 | 0.85 | DHFR (0.66) | DHFRHEXAHEXBALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL4530122 | 0.84 | DHFR (0.47) | DHFRHEXAHEXBALDH1A1HPGD | |
| SCHEMBL12368257 | 0.84 | HEXA (0.64) | DHFRHEXAHEXBALDH1A1LMNA | |
| SCHEMBL1885367 | 0.84 | HEXA (0.50) | DHFRHEXAHEXBALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL1889973 | 0.82 | HEXA (0.49) | DHFRHEXAHEXBALDH1A1LMNA | |
| SCHEMBL12368259 | 0.82 | HEXA (0.68) | DHFRHEXAHEXBALDH1A1NPC1 | |
| SCHEMBL1882625 | 0.82 | MAP4K4 (0.57) | DHFRHEXAHEXBRAB9ASMN1; SMN2 | |
| SCHEMBL4526810 | 0.81 | HEXA (0.47) | DHFRHEXAHEXBALDH1A1LMNA | |
| SCHEMBL12368258 | 0.81 | HEXA (0.47) | DHFRHEXAHEXBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | HOSPITAL FOR SICK CHILDREN (CA) | 2015-10-01 | — | — | US | disclosed |
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | HOSPITAL FOR SICK CHILDREN (CA) | 2015-10-01 | — | — | US | disclosed |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | GAA, GBA1, MAN2B1 | DHFR 960/4885HEXA 48/4885HEXB 59/4885 |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | GAA, GBA1, MAN2B1 | DHFR 960/4885HEXA 48/4885HEXB 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.